Teresa Company Messa: ”Evolution, Commitment, and Innovation” Perfectly Sum up Last Week’s Event
Teresa Company Messa, Market Development Manager at Werfen, shared on LinkedIn:
”Evolution, commitment, and innovation
Three big words, but ones that perfectly sum up last week’s event: the launch of the 70 Series, a new generation of analyzers that mark another step forward in our mission to advance hemostasis diagnostics.
And there could be no better setting than La Pedrera.
Just as Gaudí challenged the limits of his time to transform architecture, we continue to push the limits of technology to transform diagnostics.
And for those of you who are not part of this world, you may ask yourselves: what does this have to do with me?
Everything.
Because behind every sample there is a person, and that person could be you, it could be me.
At Werfen, we work every day with a firm commitment to ensuring the highest quality, accuracy, and service for laboratory professionals and, ultimately, for patients.”
Stay updated with Hemostasis Today.
-
Oct 9, 2026, 12:03Heather Case: Bridging Awareness and Action in Women’s Hemophilia Care
-
Oct 9, 2026, 11:58Brandon Luu: Can Iron Deficiency Cause Fatigue Without Anemia?
-
Oct 9, 2026, 11:51Sumaiya Dickens: Marginal Zone B Cells in Transfusion Medicine and Hemophilia A Research
-
Oct 9, 2026, 11:44Ayyappan V Nair: PRP and Rehabilitation – Can It Help Athletes with Partial Rotator Cuff Tears?
-
Oct 9, 2026, 11:29Jigesha Dholakia: Supporting the Hemophilia Community Through the Unite Walk
-
Oct 9, 2026, 11:06Nobles Green: How siRNA Therapy Helps the Body Form Stronger Clots
-
Oct 9, 2026, 10:53Switching From Emicizumab to Denecimig in Hemophilia A – Rare Disease Advisor
-
Oct 9, 2026, 10:40What New U.S. Data Reveal About GT – Glanzmann’s Research Foundation
-
Oct 9, 2026, 10:32Anjali Pandey: The Morphologic Clues to MDS With del(5q)